Company Focus
UCB
Latest UCB News
Pharmaceutical
April 2026 saw continued strong momentum in pharmaceutical M&A, building on the active first quarter and reinforcing the sector’s shift toward strategic, innovation-led acquisitions. 6 May 2026
Related News
Insights
Company Spotlight
A Tokyo-headquartered biotechnology company leveraging its GPCR structure-based drug discovery platform to build a diversified pipeline spanning neuropsychiatric disorders, rare diseases, and autoimmune conditions across global markets.
Latest News & Features of interest to UCB
Biotechnology
San Diego-based Capricor Therapeutics, a biotech developing cell and exosome-based therapeutics for rare diseases, has filed a lawsuit Japanese pharma against Nippon Shinyaku and its US subsidiary, NS Pharma. 11 May 2026
Pharmaceutical
Japanese drugmaker Nxera Pharma has entered into a license agreement with a newly established company (NewCo) to advance a specific GPCR-targeted program owned by Nxera. Nxera shares rose 6.4% to 1,242 yen on the news. 11 May 2026
Pharmaceutical
Among important regulatory news last week, the US Food and Drug Administration (FDA) approved Axsome Therapeutics’ Alzheimer’s agitation candidate Auvelity, and an FDA Advisory Committee voted against approval of AstraZeneca’s breast cancer drug camizestrant. US biotech Madrigal Pharma revealed a deal with Arrowhead Pharma to acquire rights to its investigational MASH treatment ARO-PNPLA3. Germany’s Bayer announced its proposed acquisition of Perfuse Therapeutic, aiming to reinforce it ophthalmics drug pipeline. 10 May 2026
Biotechnology
The US Food and Drug Administration (FDA) late Friday approved a label expansion for Netherlands-based argenx’ Vyvgart efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG). 9 May 2026
Pharmaceutical
An interview with Francesco Di Marco, the new chief executive of Italfarmaco. 8 May 2026
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Japanese drugmaker Otsuka’s Dawnzera (donidalorsen) to prevent angioedema attacks. 7 May 2026
Pharmaceutical
Shares of Catalyst Pharmaceuticals are trading at around $30.52 to $31.50, following an announcement that Italy’s Angelini Pharma will acquire the company for $31.50 per share in cash. 7 May 2026
Pharmaceutical
April 2026 saw continued strong momentum in pharmaceutical M&A, building on the active first quarter and reinforcing the sector’s shift toward strategic, innovation-led acquisitions. 6 May 2026
Biotechnology
Japanese drugmaker Takeda said its investigational immunoglobulin therapy TAK-881 met the primary endpoint in a pivotal Phase II/III study in patients with primary immunodeficiency disease, strengthening the company’s position in a steadily growing plasma therapies market. 6 May 2026
Biotechnology
Privately-held Windward Bio, a Swiss biotech focused on serious immunological diseases, has announced an upsized $165 million crossover financing. 5 May 2026
Latest In Brief for UCB
Biotechnology
US Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a US appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular dystrophy (DMD) treatment, according to a Reuters report. 23 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze